MGNX (Macrogenics) Beta: 0.6871 (As of Jun. 25, 2026)


MGNX Macrogenics Inc MGNX
47 GF Score
Price $4.76
GF Value $4.08
Valuation Modestly Overvalued
! 8 Warning Signs
View Full Analysis

What is Macrogenics Beta?

Macrogenics MGNX +1.92% 47 Beta is 0.6871 as of Jun. 25, 2026. GuruFocus rates MGNX with a GF Score™ of 47/100 and a GF Value™ of $4.08 (Modestly Overvalued). The stock has 8 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-25), Macrogenics's Beta is 0.6871.


Macrogenics  (NAS:MGNX) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Macrogenics Beta Related Terms


Macrogenics Beta Historical Data

* Premium members only.

The historical data trend for Macrogenics's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Macrogenics Beta Chart

Macrogenics Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.95 2.33 1.90 1.58 1.24

Macrogenics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 1.74 1.26 1.66 1.24 0.27

MGNX vs CNTX, TARA, ACIU: Beta Comparison

For the Biotechnology subindustry, Macrogenics's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Macrogenics Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Macrogenics's Beta distribution charts can be found below:

* The bar in red indicates where Macrogenics's Beta falls into.


MGNX
47GF Score
Macrogenics Inc MGNX
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Macrogenics Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.6871 mean?
Macrogenics (MGNX) has a Beta of 0.6871 as of Jun. 25, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Macrogenics and its competitors.
Is Macrogenics' Beta too high?
Macrogenics' current Beta is 0.6871. Overall, Macrogenics has a GF Score™ of 47/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Macrogenics' Beta compare to CNTX and TARA?
Macrogenics' Beta of 0.6871 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Macrogenics and its competitors. Macrogenics's current Beta is 0.6871. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Macrogenics stock overvalued right now?
Based on GuruFocus' analysis, Macrogenics (MGNX) is currently considered Modestly Overvalued. The stock's GF Value™ is $4.08, compared to a current price of $4.76 — trading 16.7% above its estimated fair value. The current Beta is 0.6871. Macrogenics' overall GF Score™ is 47/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Macrogenics (MGNX), the current Beta is 0.6871 as of Jun. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Macrogenics (MGNX) Overvalued in 2026?

Based on GuruFocus' analysis, Macrogenics stock appears to be overvalued. The current stock price of $4.76 is trading 16.7% above its estimated GF Value™ of $4.08. GuruFocus considers Macrogenics to be Modestly Overvalued.

Key valuation signals for MGNX:

  • Beta: 0.6871
  • GF Value™: $4.08 vs. price of $4.76 (16.7% above fair value)
  • GF Score™: 47/100 with 8 warning signs

No single metric tells the full story. See the MGNX stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Macrogenics Business Description

Other Exchanges M55:Germany
Address 9704 Medical Center Drive, Rockville, MD, USA, 20850
Macrogenics Inc is a clinical-stage biopharmaceutical company focused on developing antibody-based therapeutics for the treatment of cancer. The company is currently developing therapeutics utilizing multiple modalities, including antibody-drug conjugates (ADCs) and multi-specific antibodies (which it refers to as DART and TRIDENT molecules). It is advancing three proprietary product candidates in clinical development: lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload, and MGC028, an ADC that targets ADAM9 and delivers a novel TOP1i-based linker-payload. Its segment is developing and commercializing monoclonal antibody-based therapeutics.
47GF Score

Get the complete analysis for MGNX

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$4.76
Price
$4.08
GF Value